Abstract：
Advances in treatment have improved the survival of multiple myeloma (MM) patients, but the disease remains incurable. Here, in this nationwide retrospective real-world evidence (RWE) study, we report the patient characteristics, incidence, overall survival outcomes, comorbidities, and healthcare resource utilization (HCRU) of all adult MM patients diagnosed between 2000 and 2021 in Finland. A total of 7070 MM patients and their 21,210 age-, sex- and region-matched controls were included in the analysis. The average MM incidence doubled from 4.11 to 8.33 per 100,000 people during the follow-up. The average age-standardized incidence also showed a significant increase over time (2.51 in 2000 to 3.53 in 2021). An increase in incidence was particularly seen in older population, indicative of improved diagnosis praxis. The median overall survival (mOS) of the MM patients and their matched controls was 3.6 and 15.6 years, respectively. The mOS of all MM patients increased significantly from 2.8 years (2000-2004) to 4.4 years (2017-2021) during the follow-up period. Distinctively, in patients who received autologous stem cell transplantation (ASCT), the mOS was 9.2 years, while in patients who did not receive ASCT, the mOS was only 2.7 years. MM patients showed more comorbidities at index and increased HCRU than their matched controls. The longer median survival and decreased risk of death indicate improved treatment outcomes in MM patients in Finland.
摘要：
治疗的进展提高了多发性骨髓瘤（MM）患者的生存率，但是这种疾病仍然无法治愈。这里,在这项全国性的回顾性真实世界证据(RWE)研究中，我们报告病人的特征，发病率,总体生存结果，合并症,以及2000年至2021年间在芬兰诊断出的所有成年MM患者的医疗资源利用(HCRU)。总共7070名MM患者和他们的21,210岁-，性别和地区匹配的对照纳入分析.在随访期间，平均MM发病率从每100,000人中的4.11增加到8.33。年龄标准化的平均发病率也随着时间的推移显着增加（2000年为2.51，2021年为3.53）。发病率的增加在老年人群中尤为明显，表明诊断实践有所改善。MM患者及其匹配对照组的中位总生存期（mOS）为3.6年和15.6年，分别。在随访期间，所有MM患者的mOS从2.8年（2000-2004年）显着增加到4.4年（2017-2021年）。特别是,在接受自体干细胞移植（ASCT）的患者中，MOS是9.2年，而在没有接受ASCT的患者中，MOS只有2.7年。与匹配的对照组相比，MM患者在指数上表现出更多的合并症和增加的HCRU。在芬兰，中位生存期延长和死亡风险降低表明MM患者的治疗结果改善。
